Denali Therapeutics (NASDAQ:DNLI) Rating Increased to Hold at Wall Street Zen

by · The Cerbat Gem

Wall Street Zen upgraded shares of Denali Therapeutics (NASDAQ:DNLI – Free Report) from a sell rating to a hold rating in a report released on Saturday,Wall Street Zen reports.

A number of other analysts also recently issued reports on DNLI. Morgan Stanley lifted their price objective on shares of Denali Therapeutics from $35.00 to $36.00 and gave the company an “overweight” rating in a report on Thursday, July 23rd. Sanford C. Bernstein restated a “hold” rating on shares of Denali Therapeutics in a report on Monday, June 22nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Denali Therapeutics in a research note on Friday, July 17th. Robert W. Baird set a $34.00 price target on shares of Denali Therapeutics in a research report on Friday, August 7th. Finally, Wedbush reissued an “outperform” rating and set a $26.00 price target on shares of Denali Therapeutics in a research report on Monday, July 13th. Thirteen research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $35.85.

View Our Latest Analysis on DNLI

Denali Therapeutics Price Performance

Shares of NASDAQ DNLI opened at $19.72 on Friday. The firm has a market cap of $3.15 billion, a PE ratio of -6.94 and a beta of 1.01. The company has a current ratio of 8.37, a quick ratio of 8.32 and a debt-to-equity ratio of 0.01. Denali Therapeutics has a 1-year low of $12.58 and a 1-year high of $27.30. The company has a fifty day moving average price of $23.42 and a 200 day moving average price of $21.87.

Denali Therapeutics (NASDAQ:DNLI – Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.68) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.17). The business had revenue of $3.60 million during the quarter, compared to analysts’ expectations of $2.15 million. During the same quarter last year, the company earned ($0.72) earnings per share. Research analysts predict that Denali Therapeutics will post -2.67 earnings per share for the current fiscal year.

Insider Buying and Selling at Denali Therapeutics

In other news, insider Alexander O. Schuth sold 2,857 shares of the company’s stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $25.07, for a total value of $71,624.99. Following the sale, the insider directly owned 281,763 shares of the company’s stock, valued at approximately $7,063,798.41. This represents a 1.00% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 9.70% of the stock is owned by corporate insiders.

Institutional Trading of Denali Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. BlackRock Inc. bought a new position in Denali Therapeutics during the second quarter worth $360,759,000. Temasek Holdings Private Ltd grew its position in shares of Denali Therapeutics by 30.9% in the fourth quarter. Temasek Holdings Private Ltd now owns 7,012,974 shares of the company’s stock valued at $115,784,000 after purchasing an additional 1,657,142 shares during the last quarter. Norges Bank bought a new position in shares of Denali Therapeutics during the fourth quarter worth approximately $84,525,000. Dimensional Fund Advisors LP lifted its holdings in Denali Therapeutics by 13.4% during the 1st quarter. Dimensional Fund Advisors LP now owns 2,692,175 shares of the company’s stock worth $51,687,000 after purchasing an additional 317,872 shares during the last quarter. Finally, Fisher Asset Management LLC lifted its holdings in Denali Therapeutics by 58.7% during the 4th quarter. Fisher Asset Management LLC now owns 2,589,403 shares of the company’s stock worth $42,751,000 after purchasing an additional 957,907 shares during the last quarter. Institutional investors own 92.92% of the company’s stock.

Denali Therapeutics Company Profile

(Get Free Report)

Denali Therapeutics Inc is a biotechnology company focused on discovering and developing medicines for patients with neurodegenerative diseases. The company is headquartered in South San Francisco, California, and was founded in 2013 by a team that included Chief Executive Officer Ryan Watts.

Denali’s research is built around its blood-brain barrier transport technologies, which are designed to help therapeutic molecules reach the brain. The company applies these technologies to potential treatments for conditions including Parkinson’s disease, Alzheimer’s disease, amyotrophic lateral sclerosis, lysosomal storage disorders and other neurodegenerative diseases.

Its pipeline has included investigational therapies directed at targets such as LRRK2, TREM2 and RIPK1, as well as enzyme-replacement approaches intended to improve delivery of treatments to the central nervous system.

Featured Stories